Lisata Therapeutics Inc (LSTA) Stock Analysis
Verdict: AVOID
With 12 months of cash runway ($15.96M cash vs ~$16M burn), LSTA faces acute dilution risk despite Phase 2 clinical pipeline potential.
Investment score: 29/100
Analysis as of
Is Lisata Therapeutics Inc stock worth reviewing? AI model thesis
Lisata Therapeutics is a micro-cap clinical-stage biopharmaceutical company ($13.97M market cap) with approximately 12 months of operational runway ($15.96M cash against -$15.98M annual FCF burn). Recent analyst downgrades to Hold/Neutral reinforce high refinancing and dilution risks ahead of Phase 2 clinical readouts.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Lisata Therapeutics Inc opportunities and risks
What speaks for LSTA
- Phase 2 clinical candidates (HONEDRA with SAKIGAKE designation, XOWNA, and CLBS201) provide binary upside catalysts if trial readouts succeed.
What speaks against LSTA
- Acute equity dilution risk driven by a 12-month cash runway ($15.96M cash balance vs -$15.98M annual FCF burn).
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| LSTA | n/a | 141.1x | n/a | 95.0% | -14621.0% | -87.3% |
| BCDA | n/a | 0.0x | n/a | 0.0% | 0.0% | -50.4% |
| SYBX | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.4% |
| PASG | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -234.8% |
| AKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -119.5% |
| PHIO | n/a | 0.0x | n/a | 0.0% | 0.0% | -89.1% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -89.1% |
Frequently asked questions about Lisata Therapeutics Inc (LSTA)
Is LSTA stock a good investment?
The cached TradeMates AI model rates Lisata Therapeutics Inc as AVOID with an investment score of 29/100. Lisata Therapeutics is a micro-cap clinical-stage biopharmaceutical company ($13.97M market cap) with approximately 12 months of operational runway ($15.96M cash against -$15.98M annual FCF burn). Recent analyst downgrades to Hold/Neutral reinforce high refinancing and dilution risks ahead of Phase 2 clinical readouts. This is algorithmic model output, not personal investment advice.
Is LSTA stock a buy?
The TradeMates model verdict for LSTA is AVOID with an investment score of 29/100. Treat this as a model signal to review, not a personal buy recommendation.